Dapagliflozin for the treatment of heart failure with reduced ejection fraction in Brazil: a cost-effectiveness analysis

Autores na Equipe: Ivan Ricardo Zimmermann, Henry Maia Peixoto
Periódico/Edição: The Lancet Regional Health &#8211; Americas
Ano: 2025
Link para acesso: <a href="https://www.sciencedirect.com/science/article/pii/S2667193X24002953?via%3Dihub">https://www.sciencedirect.com/science/article/pii/S2667193X24002953?via%3Dihub

Dapagliflozin for the treatment of heart failure with reduced ejection fraction in Brazil: a cost-effectiveness analysis